Janney Montgomery Scott
LGND icon

Janney Montgomery Scott’s Ligand Pharmaceuticals LGND Stock Holding History

Janney Montgomery Scott’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$558K Buy
+1,764
New +$416K ﹤0.01% 2326
2019
Q1 		– Sell
-46,756
Closed -$3.96M – 2047
2018
Q4 		$3.96M Sell
46,756
-1,400
-3% -$149K 0.04% 422
2018
Q3 		$8.25M Sell
48,156
-601
-1% -$90.6K 0.07% 294
2018
Q2 		$6.3M Buy
48,757
+5,080
+12% +$567K 0.06% 324
2018
Q1 		$4.5M Sell
43,677
-657
-1% -$65K 0.05% 400
2017
Q4 		$3.79M Sell
44,334
-1,077
-2% -$93.3K 0.04% 438
2017
Q3 		$3.86M Buy
+45,411
New +$3.6M 0.04% 406
2017
Q2 		– Sell
-3,929
Closed -$259K – 1781
2017
Q1 		$259K Sell
3,929
-1,125
-22% -$74K ﹤0.01% 1481
2016
Q4 		$320K Buy
5,054
+1,407
+39% +$88.8K ﹤0.01% 1291
2016
Q3 		$232K Buy
+3,647
New +$268K ﹤0.01% 1319
2015
Q3 		– Sell
-3,429
Closed -$216K – 1429
2015
Q2 		$216K Buy
+3,429
New +$187K ﹤0.01% 1737

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janney Montgomery Scott's LGND Position: Q2 2026 in Review

Janney Montgomery Scott opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1,764 shares worth $558K. The stake represents ﹤0.01% of the portfolio and ranks #2326 among its holdings. This is a return to the name: Janney Montgomery Scott previously reported a position in LGND as recently as Q4 2018.

Janney Montgomery Scott first reported a position in LGND in Q2 2015 and has held it in 11 quarters since. The position peaked at $8.25M in Q3 2018. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Janney Montgomery Scott held 1,764 shares of Ligand Pharmaceuticals worth $558K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Janney Montgomery Scott position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Janney Montgomery Scott's portfolio in Q2 2026, its #2326 holding.
  • Janney Montgomery Scott first reported a position in Ligand Pharmaceuticals in Q2 2015 and has held it in 11 quarters since.
  • Janney Montgomery Scott's Ligand Pharmaceuticals position peaked at $8.25M in Q3 2018.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.